TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01973153

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Motivational Counseling (BMC)
Description: 3-5 minute BMC delivered by clinicians and nurses at well, sick, and WIC visits with the goal of reducing obesogenic behaviors. During BMC, the medical team facilitates the selection of a specific goal (i.e., reduce sugar sweetened beverage consumption) that is meaningful to the mother and teaches the mother simple behavioral strategies.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Motivational Counseling (BMC)
Description: 3-5 minute BMC delivered by clinicians and nurses at well, sick, and WIC visits with the goal of reducing obesogenic behaviors. During BMC, the medical team facilitates the selection of a specific goal (i.e., reduce sugar sweetened beverage consumption) that is meaningful to the mother and teaches the mother simple behavioral strategies.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Motivational Counseling (BMC)
Description: 3-5 minute BMC delivered by clinicians and nurses at well, sick, and WIC visits with the goal of reducing obesogenic behaviors. During BMC, the medical team facilitates the selection of a specific goal (i.e., reduce sugar sweetened beverage consumption) that is meaningful to the mother and teaches the mother simple behavioral strategies.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Motivational Counseling Plus Phone Calls (BMC + Phone)
Description: BMC as described above that is supplemented by monthly telephone contacts with community health workers designed to identify and overcome barriers to goal progress.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Motivational Counseling Plus Home Visits (BMC + Home)
Description: BMC as described above that is supplemented by monthly home visits with community health workers designed to identify and overcome barriers to goal progress.
Study: NCT03408405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar Gel 80 UNT/ML Injectable Solution
Description: Participant will self inject 'Acthar Gel 80 UNT/ML Injectable Solution' 2 x per week for six months.
Study: NCT02702778

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Delayed-Release (DR) Prednisone
Description: delayed release prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Delayed-Release (DR) Prednisone
Description: delayed release prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Delayed-Release (DR) Prednisone
Description: delayed release prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Release (IR) Prednisone
Description: standard prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Release (IR) Prednisone
Description: standard prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Release (IR) Prednisone
Description: standard prednisone
Study: NCT02783573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanabecestat
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanabecestat
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanabecestat
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanabecestat
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study: NCT01145989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT9283
Description: Starting dose will be 40 mg/m2/day OR 30 mg/m2/day to be confirmed at registration. IV 24 hour continuous infusion Days 1 and 8 every three weeks
Study: NCT02517177

Intervention type: OTHER
Group type: OTHER
Intervention: Parabolic flight

Intervention type: OTHER
Group type: OTHER
Intervention: Cardiovascular parameters measurements
Study: NCT02611453

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Air contrast cholangiography using carbon dioxide gas
Description: Carbon dioxide (CO2) will be injected into the biliary tree (which is already exposed to CO2 during routine ERCP) and images will be obtained by using fluoroscopy and digital subtraction imaging (a specific setting on certain fluoroscopy tables).
Study: NCT02986191

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mucograft
Description: This method of grafting will be used to treat the gingival recession using coronally advanced flaps.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Connective Tissue Graft
Description: This will be used in the traditional manner to correct gingival recession
Study: NCT00821262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Study: NCT01681277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608 PIB bid
Description: powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 113608 PIB bid
Description: powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 113608 PIB bid
Description: powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 113608 PIB qd
Description: powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 113608 PIB bid
Description: powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608 PIB bid
Description: powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608 PIB bid
Description: powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608 PIB qd
Description: powder for oral solution
Study: NCT01200342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genasense
Description: 900 mg by vein over 1 hour on Days 1, 3, and 5 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m\^2 by vein over 3 hours on Day 3 of a 21 day cycle following Genasense.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin starting dose in mg (AUC= 6) is administered over 30 minutes IV Piggyback (IVPB). Carboplatin will be dosed after Paclitaxel dose on Day 3 every 3 weeks.~The total dose of Carboplatin is calculated using a formula based upon a participant's glomerular filtration rate (GFR in mL/min) and Carboplatin target area under the concentration (AUC).
Study: NCT03953924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transtheoretical model-based (TTM - based) intervention and motivational interviewing (MI)
Description: The MI was implemented 2 times, 20 minutes each time, the trained nurse interviewed each patient face-to-face by bedside. Based on the evaluation results and motivational interviewing, the change stages of the patients' behavior changes were identified. According to the changing stage,TTM - based intervention was given 3 times in the form of a small course, 20 minutes each time, the key point was divided into three stages.
Study: NCT04617249

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: median anesthesia
Description: giving median anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: paramedian anesthesia
Description: giving paramedian anesthesia
Study: NCT02812095

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Refeeding
Description: when amount of feeding reach to 120mL/kg a day,
Study: NCT00371384

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: massage
Description: UP to 10 massages over 10 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: massage
Description: UP to 10 massages over 10 weeks
Study: NCT04411004

Intervention type: DIAGNOSTIC_TEST
Intervention: Transvaginal ultrasound
Description: Transvaginal ultrasonographic scan to diagnosis the recurrence of rectal endometriosis
Study: NCT03924388

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural spinal cord stimulation
Description: The measurements will be obtained in 2 positions of supine and \~ 70° upright adjusted by the tilt-up table.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trnascutaneous electrical spinal cord stimulation.
Description: The measurements will be obtained in 2 positions of supine and \~ 70° upright adjusted by the tilt-up table.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trnascutaneous electrical spinal cord stimulation.
Description: The measurements will be obtained in 2 positions of supine and \~ 70° upright adjusted by the tilt-up table.
Study: NCT03560453

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project SEARCH Plus ASD Supports
Description: Project SEARCH is an intensive 9-month job training program where youth with developmental disabilities in their last year of high school are embedded in a large community business such as a hospital, government complex, or banking center (Daston et al., 2012). Students with developmental disabilities who participate in this model rotate through three 10-12 week internships within the business where they log approximately 720 hours of internship time learning marketable skills while receiving supported employment. They also get 180 hours of classroom time at the business for a total of approximately 900 hours embedded in the business setting. In addition to these important training components, Project SEARCH requires collaboration between multiple community partners to support students in attaining employment upon completion of the program. Collaborations include students with developmental disabilities and their family, a LEA, a local CRP, the state VR, and a host business.
Study: NCT01834456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Med Complex Children Intervention
Description: Comprehensive Care, including creating a care plan, offering and integrating developmental and behavioral care, with added care coordination in a Medical Home/Primary Care Practice
Study: NCT01996111

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Injection of 1.0 cc of 0.9% Saline
Description: Injection of 1.0 cc of 0.9% Saline into affected area

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension
Description: Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension into affected area
Study: NCT04411004

Intervention type: BEHAVIORAL
Intervention: 5-point Likert scale
Description: Subjective scale to evaluate satisfaction to previous surgical treatment for rectal endometriosis
Study: NCT00088933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant fowlpox-CEA(6D)/TRICOM vaccine
Description: Given intradermally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant fowlpox-CEA(6D)/TRICOM vaccine
Description: Given intradermally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant fowlpox-CEA(6D)/TRICOM vaccine
Description: Given intradermally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant fowlpox-CEA(6D)/TRICOM vaccine
Description: Given intradermally
Study: NCT01996111

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension
Description: Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension into affected area

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension
Description: Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension into affected area
Study: NCT02162160

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: probiotic creme
Description: Probiotic creme applied
Study: NCT00088933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant fowlpox-CEA(6D)/TRICOM vaccine
Description: Given intradermally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant fowlpox-CEA(6D)/TRICOM vaccine
Description: Given intradermally
Study: NCT02162160

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Creme without probiotics applied in same manner
Study: NCT01648062

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Self-Regulation Using Mental Imagery
Description: Comparison of two forms of mental imagery to instigate behaviors that assist in the sleeping process

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Self-Regulation Using Mental Imagery
Description: Comparison of two forms of mental imagery to instigate behaviors that assist in the sleeping process

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sleep Self-Regulation Using Mental Imagery
Description: Comparison of two forms of mental imagery to instigate behaviors that assist in the sleeping process

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Self-Regulation Using Mental Imagery
Description: Comparison of two forms of mental imagery to instigate behaviors that assist in the sleeping process
Study: NCT03468725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XPF-008
Description: Capsule filled with XEN1101

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Microcrystalline Cellulose
Description: Placebo capsule
Study: NCT01492504

Intervention type: DRUG
Intervention: Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)
Description: Observational study - No Intervention \[(subjects were previously treated with Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)\]
Study: NCT01951417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene/BPO Gel
Description: Adapalene/Benzoyl Peroxide (BPO) Gel Pump (once daily)
Study: NCT00088933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant vaccinia-CEA(6D)-TRICOM vaccine
Description: Given intradermally
Study: NCT01951417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moisturizer SPF 30
Description: Moisturizer SPF 30 (once daily)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foam Wash
Description: Foam Wash (twice daily)
Study: NCT02794298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-tDCS
Study: NCT04220801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZM-H1505R
Description: Single oral doses of 300, 450, 600, 750, and 900 mg of ZM-H1505R or placebo and multiple oral doses of 450, 600, and 750 mg of ZM-H1505R or placebo will be administered in a fasted state, or in the case of Cohort 3 (Part 1), a second dose of 600 mg will be administered in the fed state. During each SAD and MAD dosing period, 2 subjects in each cohort will receive placebo instead of ZM-H1505R. The dose levels may be adjusted based on the safety and tolerability obtained from the previous cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZM-H1505R
Description: Single oral doses of 300, 450, 600, 750, and 900 mg of ZM-H1505R or placebo and multiple oral doses of 450, 600, and 750 mg of ZM-H1505R or placebo will be administered in a fasted state, or in the case of Cohort 3 (Part 1), a second dose of 600 mg will be administered in the fed state. During each SAD and MAD dosing period, 2 subjects in each cohort will receive placebo instead of ZM-H1505R. The dose levels may be adjusted based on the safety and tolerability obtained from the previous cohort.
Study: NCT00088933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant vaccinia-CEA(6D)-TRICOM vaccine
Description: Given intradermally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant vaccinia-CEA(6D)-TRICOM vaccine
Description: Given intradermally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant vaccinia-CEA(6D)-TRICOM vaccine
Description: Given intradermally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant vaccinia-CEA(6D)-TRICOM vaccine
Description: Given intradermally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant vaccinia-CEA(6D)-TRICOM vaccine
Description: Given intradermally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given subcutaneously
Study: NCT01747499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Study: NCT06312800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acamprosate
Description: Randomized allocation of treatments will guide the dispensation of treatments in one of 6 possible sequences--ex, M (methazolamide)- P(placebo)-A (Acamprosate); or PAM or MAP or PMA or AMP or APM. Biostatistician will devise medication randomization strategies and investigators and staff will be blinded.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Randomized allocation of treatments will guide the dispensation of treatments in one of 6 possible sequences--ex, M (methazolamide)- P(placebo)-A (Acamprosate); or PAM or MAP or PMA or AMP or APM. Biostatistician will devise medication randomization strategies and investigators and staff will be blinded.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methazolamide
Description: Randomized allocation of treatments will guide the dispensation of treatments in one of 6 possible sequences--ex, M (methazolamide)- P(placebo)-A (Acamprosate); or PAM or MAP or PMA or AMP or APM. Biostatistician will devise medication randomization strategies and investigators and staff will be blinded.
Study: NCT02688933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HOE901-U300 (Insulin Glargine 300 U/ml)
Description: Self-administered by subcutaneous (SC) injection in the morning (between waking up and breakfast) using a pre-filled pen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus (Insulin Glargine 100 U/ml)
Description: Self-administered by subcutaneous (SC) injection in the morning (between waking up and breakfast using a pre-filled pen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mandated back ground therapy
Description: Rapid insulin analogs: e.g., insulin glulisine, insulin lispro or insulin aspart, used by participant at least 30 days before screening. Mealtime insulin was to be continued during the study and titrated towards protocol specified postprandial glucose targets (130-180 mg/dL).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mandated back ground therapy
Description: Rapid insulin analogs: e.g., insulin glulisine, insulin lispro or insulin aspart, used by participant at least 30 days before screening. Mealtime insulin was to be continued during the study and titrated towards protocol specified postprandial glucose targets (130-180 mg/dL).
Study: NCT00828113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: Extension of 1 mg twice daily treatment to 52 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline
Description: Extension of 1 mg twice daily treatment to 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: Double-blind switch to placebo after 12 weeks of open-label therapy
Study: NCT03917862

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: TDM-621
Description: The TDM-621 is a topic hemostatic product which will be used during ascending aortic surgery.
Study: NCT00557908

Intervention type: DRUG
Intervention: VWF/FVIII products
Description: Participants in the prospective phase of the study undergo an escalation of treatment from receipt of one to three levels of VWD product. All subjects enrolled will begin treatment on the level one and remain on this regimen for the duration of follow-up, or until they meet the criteria for escalation to level two or three (if indeed they do meet the criteria.)~Dosing for joint bleeding, epistaxis, and GI bleeding indications: 50 U RCo/kg once per week, 50 U RCo/kg twice per week, or 50 U RCo/kg three times per week.~Dosing for menorrhagia: 50 U RCo/kg on day 1 of menses for 2 cycles, 50 U RCo/kg on days 1 and 2 of menses for 2 cycles, or 50 U RCo/kg on days 1, 2, and 3 of menses
Study: NCT04523428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax/Acalabrutinib
Description: All patients will receive a lead-in with 2 cycles of acalabrutinib 100 mg bid. Hereafter patients will continue with ramp-up of venetoclax followed by daily 400 mg venetoclax in combination with acalabrutinib for 24 cycles. Patients will be treated until they have received a total of 26 cycles or until progression, whichever comes first.
Study: NCT00600327

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoTex™ NexStent™
Description: EndoTex™ NexStent™ is a flexible, fine mesh Nitinol stent used to treat patients that are at high risk of adverse events from carotid endarterectomy and require carotid revascularization of a target vessel that has a reference diameter between 4mm and 9mm and stenosis that is less than 30mm in length.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Filter Wire EZ™
Description: EPI Fliter Wire EZ™ Embolic Protection System is indicated for use as a guide wire and embolic protection system to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in coronary saphenous vein bypass grafts and carotid arteries.